Clinical Trial Update: Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Lucentis plus Tagolimumab for PD-L1-positive, HR+/HER2- advanced breast cancer after CDK4/6 inhibitors, with the study currently NOT_…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lucentis (ranibizumab)
• Tagolimumab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING